SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Indoco Remedies inches up on entering into strategic distribution partnership with Clarity Pharma, UK

03 Dec 2024 Evaluate

Indoco Remedies is currently trading at Rs. 322.10, up by 0.10 points or 0.03% from its previous closing of Rs. 322.00 on the BSE.

The scrip opened at Rs. 338.00 and has touched a high and low of Rs. 353.80 and Rs. 312.30 respectively. So far 87041 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 416.95 on 01-Jan-2024 and a 52 week low of Rs. 286.50 on 04-Jun-2024.

Last one week high and low of the scrip stood at Rs. 353.80 and Rs. 297.80 respectively. The current market cap of the company is Rs. 2969.19 crore.

The promoters holding in the company stood at 58.75%, while Institutions and Non-Institutions held 19.94% and 21.30% respectively.

Indoco Remedies has entered into strategic distribution partnership with Clarity Pharma, UK. This partnership marks a significant milestone in Indoco’s history, as the company will launch around 20 products over the next 18 months through Clarity Pharma, its distributor in the UK. The Company will continue to supply all the products under existing B2B partnership to its clients.

Indoco is a fully integrated, research-oriented pharmaceutical company with a strong global presence. The Company’s turnover is $212 million with a human capital of over 6000 employees, including over 400 skilled scientists and field staff who are the strength of the organization. Clarity Pharma has over 25 years of experience in bringing products to market and now services over 4,000 Primary Healthcare customers.

Indoco Remedies is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs) in India.


Indoco Remedies Share Price

248.20 7.35 (3.05%)
08-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1887.95
Dr. Reddys Labs. 1348.70
Cipla 1431.65
Zydus Lifesciences 1149.00
Lupin 2457.45
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: